Ocular Therapeutix, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company expects total net product revenue to be in the range of $48 to $52 million, representing growth of between 10% to 20% over 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.875 USD | +1.29% | -5.35% | +30.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.94% | 898M | |
+38.94% | 728B | |
+33.05% | 603B | |
-5.53% | 360B | |
+18.82% | 332B | |
+1.54% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.44% | 164B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022